Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.13

Mkt cap

467M

Volume

3.3M

High

2.38

P/E Ratio

-3.54

52-wk high

3.40

Low

2.13

Div yield

N/A

52-wk low

1.15

Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:47 pm

Esperion Therapeutics forecasts its FY24 operating expenses to be between $225M-$245M, which includes $20M in non-cash expenses due to stock compensation.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:10 am

Esperion Therapeutics reported a 44% year-over-year growth in Q4 retail prescription equivalents and projects continued momentum in this segment into the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:06 am

Esperion Therapeutics (NASDAQ:ESPR) reported Q4 earnings with a loss of $(0.50) per share, missing the $(0.48) estimate, but sales of $32.25M exceeded the $28.70M estimate, marking a 71.38% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:03 am

Numerous companies are scheduled to report their earnings on February 27, 2024, covering a wide range of industries from technology and healthcare to energy and financial services. The report includes a mix of expected quarterly losses and earnings, highlighting the diverse financial health and performance outlooks within the corporate landscape.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 10:01 am

Esperion Therapeutics (NASDAQ:ESPR) is scheduled to release its quarterly earnings report on February 27, 2024, with analysts expecting an EPS of $-0.48. The company's past earnings performance shows a mix of beats and misses, with the share price reacting variably. Shares are currently trading at $2.61, down 57.04% over the last year. Investors will be keenly watching for not just the earnings outcome but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 8:02 pm

Esperion Therapeutics (NYSE:ESPR) has seen a significant decrease in short interest, with a 40.03% drop since the last report. The current short interest stands at 20.20 million shares, or 12.66% of the float. It would take about 2.65 days to cover all short positions. While a decrease in short interest can indicate a more bullish sentiment, it does not necessarily predict a near-term rise in stock price. Esperion has a higher short interest than its peer group average of 10.42%.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 6:00 pm

TransCode Therapeutics, Inc. (RNAZ) shares fell by over 24% after pricing a common stock offering at $1.22 per share. Other stocks moved in Friday's mid-day session with notable gainers including Charge Enterprises (CRGE), Kaman Corporation (KAMN), and Mesa Air Group (MESA), among others. Losers included C3is Inc. (CISS), Azitra, Inc. (AZTR), and iRobot Corporation (IRBT). The market also reacted to various company announcements such as acquisitions, earnings reports, and analyst upgrades or downgrades.

Portfolio Pulse from Avi Kapoor

January 19, 2024 | 6:05 pm

Super Micro Computer, Inc. (NASDAQ:SMCI) shares rose over 12% in pre-market trading following the company's updated Q2 financial guidance, which exceeded previous estimates. The company now expects net sales of $3.6 to $3.65 billion and non-GAAP diluted net income per share of $5.40 to $5.55. Other stocks mentioned include gainers like Treasure Global Inc. (NASDAQ:TGL) and losers such as iRobot Corporation (NASDAQ:IRBT), which dropped due to the EU's likely rejection of Amazon's acquisition.

Portfolio Pulse from Avi Kapoor

January 19, 2024 | 1:13 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Mesoblast (MESO) saw a 22.1% increase, while Sangamo Therapeutics (SGMO) rose by 20.27%. Telesis Bio (TBIO) and INVO Bioscience (INVO) also saw gains of 19.27% and 17.43%, respectively. Coherus BioSciences (CHRS) and TC BioPharm (TCBP) shares increased as well. On the downside, Esperion Therapeutics (ESPR) fell by 17.7%, Adial Pharmaceuticals (ADIL) by 15.47%, Accelerate Diagnostics (AXDX) by 10.91%, Alaunos Therapeutics (TCRT) by 9.47%, Nuwellis (NUWE) by 9.12%, and MorphoSys (MOR) by 8.7%.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.